CD3E and neoplasm: Considering the clinical approval of bispecific antibodies for cancer therapy, most of which activate T cells through engaging CD3ε in the TCR complex, we incorporated an scFv, rather than a CAR expression cassette, against two well‐known tumor antigen targets (CD19 or tumor‐associated glycoprotein 72; TAG‐72), into the N‐terminus of CD3ε to generate FP T cells.